Lonza expands antibody-drug conjugate production pact, plots 180 new hires

The abrupt departure of Lonza’s CEO last month clearly hasn’t dampened the Swiss CDMO’s dealmaking prowess.

Thursday, the company unveiled a manufacturing expansion as part of an evolving production pact that’s set to create nearly 200 new jobs at “one of the largest bioconjugation facilities globally.”